

November 13, 2025

To,**Listing Department,****BSE Limited**

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code- 543444**Sub: Outcome of Board Meeting & Submission of Unaudited Financial Results for Half Year ended September 30, 2025****Dear Sir / Madam,**

In continuation of our letter dated November 10, 2025, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors the Company at their meeting held today i.e. November 13, 2025 at Registered Office of the Company, inter alia considered and approved the following;

1. The Unaudited Standalone Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30, 2025 together with Statement of Assets and Liabilities and Statement of Cash Flow.
2. The Unaudited Consolidated Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30, 2025 together with Statement of Assets and Liabilities and Statement of Cash Flow.

Limited Review Report thereon for Standalone and Consolidated Financial Results pursuant to proviso to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed.

The Board Meeting commenced at 04.00 P.M. and concluded at 05:00 P.M.

The aforesaid results are also being disseminated on Company's website at <https://www.fabinolife.com/fabino-ipo/>

You are requested to kindly update above information on your record.

Thanking You,

For Fabino Enterprises Limited

(Formerly known as Fabino life sciences limited)

Aditya Mahavir Jain
(Managing Director)
DIN: 09353344



Hiren J. Maru

**AUDITORS LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS
OF THE COMPANY FOR THE HALF YEAR ENDED 30th SEPTEMBER 2025 PURSUANT TO THE
REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS)
REGULATIONS, 2015 AS AMENDED.**

**To Board of Directors of
FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)**

We have reviewed the accompanying statement of unaudited standalone financial results ("the statement") of **FABINO ENTERPRISES LIMITED** (formerly known as Fabino Life Sciences Limited) ('the Company") for the half ended 30th September 2025 being submitted by the company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries primarily of person responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR D G M S & CO.
Chartered Accountants
Firm Regn. No. 0112187W**



Hiren J. Maru
Partner
Membership No. 115279
UDIN: 25115279BMLQGS2772

Date: 13th November 2025
Place: Mumbai

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

CIN: L24100HR2011PLC114093

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murtal Road, Sonipat Haryana 131001

Statement of Standalone Unaudited Financial Results for the Half Year and Year Ended 30.09.2025

(Rupees in lakhs, Except EPS)

	Particulars	Half Year Ended			Year Ended
		30-09-2025	31-03-2025	30-09-2024	31-03-2025
A	Date of start of reporting period	01-04-2025	01-10-2024	01-04-2024	01-04-2024
B	Date of end of reporting period	30-09-2025	31-03-2025	30-09-2024	31-03-2025
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
Part I					
I	Revenue From Operations				
	Net sales or Revenue from Operations	67.99	1,378.49	425.12	1,803.60
II	Other Income	14.60	18.17	10.68	28.85
III	Total Revenue (I + II)	82.59	1,396.66	435.80	1,832.46
IV	Expenses				
(a)	Cost of materials consumed	-	-	-	-
(b)	Purchases of stock-in-trade	20.48	1,058.22	577.43	1,635.66
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	47.24	224.56	(211.39)	13.17
(d)	Employee benefit expense	10.38	15.20	11.91	27.11
(e)	Finance Costs	8.10	7.45	5.52	12.96
(f)	Depreciation and amortisation expense	5.33	4.11	2.48	6.59
(g)	Other Expenses	15.59	67.41	43.63	111.04
	Total expenses	107.13	1,376.94	429.58	1,806.52
V	Profit (Loss) before Exceptional and	(24.55)	19.72	6.22	25.93
VI	Exceptional items				
VII	Share of Profit/(Loss) of Associates				
VIII	Profit (Loss) before Tax (VII-VII)	(24.55)	19.72	6.22	25.93
X	Tax Expense				
(a)	Current Tax	0.00	11.04	1.65	12.68
	(Less):- MAT Credit				
	Current Tax Expense Relating to Prior years				
(b)	Deferred Tax (Asset)/Liabilities	0.33	0.15	(0.08)	0.06
XI	Net Profit/Loss for the period from Continuing Operations (IX-X)	(24.87)	8.53	4.65	13.19
XII	Profit (Loss) from Discontinuing Operations				
XIII	Tax Expenses of Discontinuing Operations				
XIV	Net Profit (Loss) from Discontinuing Operations after tax (XII-XIII)				
XV	Profit (Loss) for the period (XI+XIV)	(24.87)	8.53	4.65	13.19
XVI	Other Comprehensive Income				
a . i)	Amount of item that will not be reclassified to profit or loss				
	ii). Income tax relating to items that will not be reclassified to profit or loss				
b . i)	Item that will be reclassified to profit or loss				
	ii). Income tax relating to items that will be reclassified to profit or loss				
XVII	Total Comprehensive income	-	-	-	-
	Total Comprehensive income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)	(24.87)	8.53	4.65	13.19
XVIII	Details of equity share capital				
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	210.00	210.00	210.00	210.00
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XIX	Reserves excluding revaluation reserve as per Balance Sheet				
XX	Earnings per share (Not Annualized for Half Year and Year ended)	-1.18	0.41	0.22	0.63
(a)	Earnings per share Continuing Operation (Not Annualised for Half Year and Year ended)				
	Basic earnings per share before extraordinary items	(1.18)	0.41	0.22	0.63
	Diluted earnings per share before extraordinary items	(1.18)	0.41	0.22	0.63
(b)	Earnings per share Discontinuing Operation (Not Annualised for Half Year and Year ended)				
	Basic earnings per share after extraordinary items	-	-	-	-
	Diluted earnings per share after extraordinary items	-	-	-	-
(c)	Earnings per share (Not Annualised for Half Year and Year ended)				
	Basic earnings per share before extraordinary items	(1.18)	0.41	0.22	0.63
	Diluted earnings per share before extraordinary items	(1.18)	0.41	0.22	0.63

Notes:-

Notes to Standalone Unaudited financials results for the half year ended September 30, 2025

- 1 The above Unaudited financial results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taken on record by the Board of Directors at its meeting held on November 13, 2025 after being reviewed by the Audit Committee.
- 2 The company has been listed on SME platform of Bse on 13th January 2022.
- 3 The company is engaged in only one business hence no information has been furnished in accordance with AS 17 on "Segment Reporting" issued by the Institute Of Chartered Accountants Of India
- 4 The aforesaid Half yearly Financial Results are also being disseminated on the website of the Company i.e. (<https://www.fabinolife.com/fabino-ipo/>)
- 5 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

FOR FABINO ENTERPRISES LIMITED

(Formerly known as Fabino Life Sciences Limited)



Aditya Mahavir Jain
Managing Director
DIN: 09353344



Date: 13th November 2025

Place :- Haryana

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001
CIN: L24100HR2011PLC114093

BALANCE SHEET AS AT 30th SEPTEMBER, 2025

(Rupees in Lakhs, unless stated otherwise)

Particulars	<i>Figures as at the end of current reporting period September 30, 2025</i>	<i>Figures as at the end of reporting period March 31, 2025</i>
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	210.00	210.00
(b) Reserves and Surplus	194.03	218.90
(c) Money received against share warrants	-	-
(2) Share Application money pending allotment		
(3) Non-Current Liabilities		
(a) Long-Term Borrowings	163.52	161.23
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long Term Provisions	-	-
(4) Current Liabilities		
(a) Short-Term Borrowings	-	-
(b) Trade Payables		
-Micro, Small and Medium Enterprises	-	-
-Others	376.47	687.11
(c) Other Current Liabilities	9.35	9.22
(d) Short-Term Provisions	14.18	14.18
Total Equity & Liabilities	967.55	1,300.64
II. ASSETS		
(1) Non-Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	42.48	46.40
(ii) Intangible Assets	-	-
(iii) Capital work-in-progress	-	-
(iv) Intangible Assets under development	-	-
(v) Fixed assets held for sale	-	-
	42.48	46.40
(b) Non-current investments	5.00	5.00
(c) Deferred tax Assets (net)	0.51	0.84
(c) Long term loans and advances	-	-
(d) Other non-current assets	6.36	6.36
(2) Current Assets		
(a) Current investments	-	-
(b) Inventories	73.06	120.30
(c) Trade receivables	640.13	874.60
(d) Cash and cash equivalents	19.64	21.76
(e) Short-term loans and advances	180.14	224.94
(f) Other current assets	0.23	0.45
Total Assets	967.55	1,300.64

FOR FABINO ENTERPRISES LIMITED

(Formerly known as Fabino Life Sciences Limited)



Aditya Mahavir Jain

Managing Director

DIN: 09353344

Date: 13th November 2025

Place : Haryana

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001

CIN: L24100HR2011PLC114093

CASH FLOW STATEMENT AS AT 30th SEPTEMBER, 2025

(Rupees in lakhs, unless stated otherwise)

Particulars	<i>Figures as at the end of current reporting period September 30, 2025</i>	<i>Figures as at the end of reporting period March 31, 2025</i>
(A) Cash flows from operating activities		
Profit for the year	(24.87)	25.93
- Finance costs	8.10	12.52
- Income tax Provision	0.33	-
Adjustments for non-cash income and expenses:		
- Depreciation & Amortisation	5.33	6.59
- Loss/(Profit) on sale/disposal of Fixed Assets	-	-
Cash flow included in investing activities:		
- Interest Income	-	-
Changes in operating assets and liabilities:		
- Decrease / (Increase) in Inventory	47.24	13.17
- Decrease / (Increase) in Trade Receivables	234.47	(252.41)
- Decrease / (Increase) in Other Current Assets	0.23	(0.45)
- Decrease / (Increase) in Other Non Current Assets	0.95	0.95
- Decrease / (Increase) in Short Term loans & Advances	44.79	(70.17)
- (Decrease) / Increase in Short Term Borrowings	-	-
- (Decrease) / Increase in Trade Payables	(310.64)	12.01
- (Decrease) / Increase in Short Term Provisions	-	244.86
- (Decrease) / Increase in Other Current Liabilities	0.13	7.42
Cash generated from operations	5.10	0.42
Income tax paid		(12.68)
Net cash from operating activities	5.10	(12.26)
(B) Cash flows from investing activities		
Sale of Fixed Assets	-	-
Investment in Shares	-	-
Interest received / (Paid)	(8.10)	(12.52)
Purchase of Fixed Assets	(1.42)	(28.90)
Net cash from investing activities	(9.52)	(41.41)
(C) Cash flows from financing activities		
Proceeds from Share Capital	-	-
Proceeds/(Repayment) from Long-term borrowings	2.30	77.69
Proceeds/(Repayment) of Other Long Current Liabilities	-	(4.50)
Net cash from financing activities	2.30	73.19
Net increase / (decrease) in cash and cash equivalents	(2.12)	19.52
Cash and cash equivalents at the beginning of year	21.77	2.25
Cash and cash equivalents at the end of year	19.64	21.77

FOR FABINO ENTERPRISES LIMITED

(Formerly known as Fabino Life Sciences Limited)



Date: 13th November 2025

Place : Haryana

Aditya Mahavir Jain

Managing Director

DIN: 09353344

**Hiren J. Maru**

AUDITORS LIMITED REVIEW REPORT ON UNAUDITED CONSOLIDATED FINANCIALS, DIRM
RESULT OF THE COMPANY FOR THE HALF YEAR ENDED 30th SEPTEMBER 2025
PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND
DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AS AMENDED.

To Board of Directors of
FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)

We have reviewed the accompanying statement of unaudited Consolidated financial results ("the statement") of Holding Company **FABINO ENTERPRISES LIMITED** (formerly known as Fabino Life Sciences Limited) ('the Company") for the half year ended 30th September 2025 and its Subsidiary Company **UPENDER METAPLAST PRIVATE LIMITED** for the half year ended 30th September 2025 being submitted by the company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This Statement is the responsibility of the company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries primarily of person responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR D G M S & CO.**Chartered Accountants**

Firm Regn. No. 0112187W

Hiren J Maru

Partner

Membership No. 115279

UDIN: 25115279BMLQGT8837

Date: 13th November 2025

Place: Mumbai

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

CIN: L24100HR2011PLC114093

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001

Statement of Consolidated Unaudited Financial Results for the Half Year and Year Ended 30.09.2025

Particulars		(Rupees in lakhs)		(Rupees in lakhs, Except EPS)	
		30-09-2025	31-03-2025	30-09-2024	31-03-2025
A	Date of start of reporting period	01-04-2025	01-10-2024	01-04-2024	01-04-2024
B	Date of end of reporting period	30-09-2025	31-03-2025	30-09-2024	31-03-2025
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
Part I					
I	Revenue From Operations				
	Net sales or Revenue from Operations	663.34	1378.49	425.12	1803.60
II	Other Income	27.56	18.35	10.68	29.03
III	Total Revenue (I + II)	690.90	1,396.84	435.80	1,832.63
IV	Expenses				
(a)	Cost of materials consumed	-	-	-	-
(b)	Purchases of stock-in-trade	546.95	1,058.22	577.43	1,635.66
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	47.24	224.56	(211.39)	13.17
(d)	Employee benefit expense	10.38	16.46	11.91	28.37
(e)	Finance Costs	8.74	6.79	6.17	12.96
(f)	Depreciation and amortisation expense	5.92	3.85	4.27	8.12
(g)	Other Expenses	90.16	71.92	43.63	115.55
	Total expenses	709.40	1,381.80	432.02	1,813.83
V	Profit (loss) before Exceptional and Extraordinary	(18.50)	15.03	3.77	18.80
VI	Exceptional items				
VII	Share of Profit/(Loss) of Associates				
VIII	Profit (loss) before Tax (VII-VII)	(18.50)	15.03	3.77	18.80
X	Tax Expense				
(a)	Current Tax	-	11.04	1.65	12.68
	(Less):- MAT Credit				
	Current Tax Expense Relating to Prior years				
(b)	Deferred Tax (Asset)/Liabilities	0.10	0.67	(0.66)	0.01
XI	Net Profit/Loss for the period from Continuing Operations (IX-X)	(18.59)	3.32	2.79	6.11
XII	Profit (Loss) from Discontinuing Operations				
XIII	Tax Expenses of Discontinuing Operations				
XIV	Net Profit (Loss) from Discontinuing Operartions after tax (XII-XIII)		-	-	-
XV	Profit (Loss) for the period (XI+XIV)	(18.59)	3.32	2.79	6.11
XVI	Other Comprehensive Income				
a . i)	Amount of item that will not be reclassified to profit or loss				
	ii). Income tax relating to items that will not be reclassified to profit or loss				
b i)	Item that will be reclassified to profit or loss				
	ii). Income tax relating to items that will be reclassified to profit or loss				
XVII	Total Comprehensive income		-	-	-
	Total Comprehensive income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)		(18.59)	3.32	2.79
XVIII	Details of equity share capital				
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)		210.00	210.00	210.00
	Face value of equity share capital (Per Share)		Rs. 10/-	Rs. 10/-	Rs. 10/-
XIX	Reserves excluding revaluation reserve as per Balance Sheet				
XX	Earnings per share (Not Annualized for Half Year and Year ended)		-0.89	0.16	0.13
(a)	Earnings per share Continuing Operation (Not Annualised for Half Year and Year ended)				
	Basic earnings per share before extraordinary items		(0.89)	0.16	0.13
	Diluted earnings per share before extraordinary items		(0.89)	0.16	0.13
(b)	Earnings per share Discontinuing Operation (Not Annualised for Half Year and Year ended)				
	Basic earnings per share after extraordinary items		-	-	-
	Diluted earnings per share after extraordinary items		-	-	-
(c)	Earnings per share (Not Annualised for Half Year and Year ended)				
	Basic earnings per share before extraordinary items		(0.89)	0.16	0.13
	Diluted earnings per share before extraordinary items		(0.89)	0.16	0.13

Notes:-

Notes to Standalone Unaudited financials results for the half year ended September 30, 2025

- The above Unaudited financial results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taken on record by the Board of Directors at its meeting held on November 13, 2025 after being reviewed by the Audit Committee.
- The company has been listed on SME platform of Bse on 13th January 2022.
- The company is engaged in only one business hence no information has been furnished in accordance with AS 17 on "Segment Reporting" issued by the Institute Of Chartered Accountants Of India
- The aforesaid Half yearly Financial Results are also being disseminated on the website of the Company i.e. (<https://www.fabinolife.com>)
- The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

FOR FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)

Aditya Mahavir Jain
Managing Director
DIN: 09353344



FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001
CIN: L24100HR2011PLC114093

Consolidated Balance Sheet as at 30th September 2025

(Rupees in Lakhs, unless stated otherwise)

Particulars	Figures as at the end of current reporting period September 30, 2025	Figures as at the end of reporting period March 31, 2025
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	210.00	210.00
(b) Reserves and Surplus	191.43	210.48
(c) Money received against share warrants	-	-
(d) Minority Interest	0.00	0.00
(2) Share Application money pending allotment		
(3) Non-Current Liabilities		
(a) Long-Term Borrowings	176.22	179.10
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long Term Provisions	-	-
(4) Current Liabilities		
(a) Short-Term Borrowings	-	-
(b) Trade Payables		
-Micro, Small and Medium Enterprises	-	-
-Others	927.83	1,141.84
(c) Other Current Liabilities	9.48	9.22
(d) Short-Term Provisions	15.18	15.18
Total Equity & Liabilities	1,530.15	1,765.82
II. ASSETS		
(1) Non-Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	42.48	55.05
(ii) Intangible Assets	-	-
(iii) Capital work-in-progress	-	-
(iv) Intangible Assets under development	-	-
(v) Fixed assets held for sale	-	-
	42.48	55.05
(b) Non-current investments	-	-
(c) Deferred tax Assets (net)	0.51	1.07
(c) Long term loans and advances	-	-
(d) Other non-current assets	6.36	6.36
(2) Current Assets		
(a) Current investments	-	-
(b) Inventories	73.06	120.30
(c) Trade receivables	1,298.15	1,417.01
(d) Cash and cash equivalents	21.80	24.38
(e) Short-term loans and advances	87.56	141.20
(f) Other current assets	0.23	0.45
Total Assets	1,530.15	1,765.82

FOR FABINO ENTERPRISES LIMITED

(Formerly known as Fabino Life Sciences Limited)



Aditya Mahavir Jain

Managing Director

DIN: 09353344

Date :- 13th November 2025

Place : Haryana

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001
CIN: L24100HR2011PLC114093


Consolidated Cash Flow Statement as at 30th September 2025

(Rupees in Lakhs, unless stated otherwise)

Particulars	<i>Figures as at the end of current reporting period September 30, 2025</i>	<i>Figures as at the end of reporting period March 31, 2025</i>
(A) Cash flows from operating activities		
Profit for the year	(18.50)	18.80
- Finance costs	8.74	12.96
- Income tax Provision	-	-
Adjustments for non-cash income and expenses:		
- Depreciation & Amortisation	5.92	8.12
- Loss/(Profit) on sale/disposal of Fixed Assets	(0.03)	-
Cash flow included in investing activities:		
- Interest Income	-	-
Changes in operating assets and liabilities:		
- Decrease / (Increase) in Inventory	47.24	13.17
- Decrease / (Increase) in Trade Receivables	118.86	(155.82)
- Decrease / (Increase) in Other Current Assets	0.22	(0.45)
- Decrease / (Increase) in Other Non Current Assets	-	0.97
- Decrease / (Increase) in Short Term loans & Advances	53.64	(49.09)
- (Decrease) / Increase in Short Term Borrowings	-	-
- (Decrease) / Increase in Trade Payables	(214.01)	156.78
- (Decrease) / Increase in Short Term Provisions	0.01	12.21
- (Decrease) / Increase in Other Current Liabilities	0.26	7.38
Cash generated from operations	2.36	25.03
Income tax paid	-	(12.68)
Net cash from operating activities	2.36	12.35
(B) Cash flows from investing activities		
Sale of Fixed Assets	8.10	-
Interest received / (Paid)	(8.74)	(12.96)
Purchase of Fixed Assets	(1.42)	(28.90)
Net cash from investing activities	(2.06)	(41.86)
(C) Cash flows from financing activities		
Proceeds from Share Capital	-	-
Proceeds/(Repayment) from Long-term borrowings	(2.88)	52.19
Proceeds/(Repayment) of Other Long Current liabilities	-	(4.50)
Net cash from financing activities	(2.88)	47.69
Net increase / (decrease) in cash and cash equivalents	(2.58)	18.18
Cash and cash equivalents at the beginning of year	24.38	6.20
Cash and cash equivalents at the end of year	21.80	24.38

FOR FABINO ENTERPRISES LIMITED

(Formerly known as Fabino Life Sciences Limited)



Aditya Mahavir Jain
Managing Director
DIN: 09353344

Date :- 13th November 2025

Place : Haryana